119 related articles for article (PubMed ID: 25988863)
1. EpCAM-Antibody-Labeled Noncytotoxic Polymer Vesicles for Cancer Stem Cells-Targeted Delivery of Anticancer Drug and siRNA.
Chen J; Liu Q; Xiao J; Du J
Biomacromolecules; 2015 Jun; 16(6):1695-705. PubMed ID: 25988863
[TBL] [Abstract][Full Text] [Related]
2. Epithelial cell adhesion molecule aptamer conjugated PEG-PLGA nanopolymersomes for targeted delivery of doxorubicin to human breast adenocarcinoma cell line in vitro.
Alibolandi M; Ramezani M; Sadeghi F; Abnous K; Hadizadeh F
Int J Pharm; 2015 Feb; 479(1):241-51. PubMed ID: 25529433
[TBL] [Abstract][Full Text] [Related]
3. Sustained expression of the RON receptor tyrosine kinase by pancreatic cancer stem cells as a potential targeting moiety for antibody-directed chemotherapeutics.
Padhye SS; Guin S; Yao HP; Zhou YQ; Zhang R; Wang MH
Mol Pharm; 2011 Dec; 8(6):2310-9. PubMed ID: 22014215
[TBL] [Abstract][Full Text] [Related]
4. Nanomedicine-mediated cancer stem cell therapy.
Shen S; Xia JX; Wang J
Biomaterials; 2016 Jan; 74():1-18. PubMed ID: 26433488
[TBL] [Abstract][Full Text] [Related]
5. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
6. EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells.
Cioffi M; Dorado J; Baeuerle PA; Heeschen C
Clin Cancer Res; 2012 Jan; 18(2):465-74. PubMed ID: 22096026
[TBL] [Abstract][Full Text] [Related]
7. Can nanomedicines kill cancer stem cells?
Zhao Y; Alakhova DY; Kabanov AV
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1763-83. PubMed ID: 24120657
[TBL] [Abstract][Full Text] [Related]
8. EpCAM Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model.
Wang T; Gantier MP; Xiang D; Bean AG; Bruce M; Zhou SF; Khasraw M; Ward A; Wang L; Wei MQ; AlShamaileh H; Chen L; She X; Lin J; Kong L; Shigdar S; Duan W
Theranostics; 2015; 5(12):1456-72. PubMed ID: 26681989
[TBL] [Abstract][Full Text] [Related]
9. Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex.
Han M; Lv Q; Tang XJ; Hu YL; Xu DH; Li FZ; Liang WQ; Gao JQ
J Control Release; 2012 Oct; 163(2):136-44. PubMed ID: 22940126
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells.
Li SY; Sun R; Wang HX; Shen S; Liu Y; Du XJ; Zhu YH; Jun W
J Control Release; 2015 May; 205():7-14. PubMed ID: 25445694
[TBL] [Abstract][Full Text] [Related]
11. Single-walled carbon nanotubes functionalized with aptamer and piperazine-polyethylenimine derivative for targeted siRNA delivery into breast cancer cells.
Mohammadi M; Salmasi Z; Hashemi M; Mosaffa F; Abnous K; Ramezani M
Int J Pharm; 2015 May; 485(1-2):50-60. PubMed ID: 25712164
[TBL] [Abstract][Full Text] [Related]
12. The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells.
Cao N; Cheng D; Zou S; Ai H; Gao J; Shuai X
Biomaterials; 2011 Mar; 32(8):2222-32. PubMed ID: 21186059
[TBL] [Abstract][Full Text] [Related]
13. Oncostatin m renders epithelial cell adhesion molecule-positive liver cancer stem cells sensitive to 5-Fluorouracil by inducing hepatocytic differentiation.
Yamashita T; Honda M; Nio K; Nakamoto Y; Yamashita T; Takamura H; Tani T; Zen Y; Kaneko S
Cancer Res; 2010 Jun; 70(11):4687-97. PubMed ID: 20484035
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo evaluation of therapy targeting epithelial-cell adhesion-molecule aptamers for non-small cell lung cancer.
Alibolandi M; Ramezani M; Abnous K; Sadeghi F; Atyabi F; Asouri M; Ahmadi AA; Hadizadeh F
J Control Release; 2015 Jul; 209():88-100. PubMed ID: 25912964
[TBL] [Abstract][Full Text] [Related]
15. Structure-directing star-shaped block copolymers: supramolecular vesicles for the delivery of anticancer drugs.
Yang C; Liu SQ; Venkataraman S; Gao SJ; Ke X; Chia XT; Hedrick JL; Yang YY
J Control Release; 2015 Jun; 208():93-105. PubMed ID: 25813888
[TBL] [Abstract][Full Text] [Related]
16. Enhanced efficacy of chemotherapy for breast cancer stem cells by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense.
Sun M; Yang C; Zheng J; Wang M; Chen M; Le DQS; Kjems J; Bünger CE
Acta Biomater; 2015 Dec; 28():171-182. PubMed ID: 26415776
[TBL] [Abstract][Full Text] [Related]
17. Co-delivery of doxorubicin and siRNA with reduction and pH dually sensitive nanocarrier for synergistic cancer therapy.
Chen W; Yuan Y; Cheng D; Chen J; Wang L; Shuai X
Small; 2014 Jul; 10(13):2678-87. PubMed ID: 24668891
[TBL] [Abstract][Full Text] [Related]
18. Dual Targeted Nanoparticles for the Codelivery of Doxorubicin and siRNA Cocktails to Overcome Ovarian Cancer Stem Cells.
Chen L; Luo J; Zhang J; Wang S; Sun Y; Liu Q; Cheng C
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511335
[TBL] [Abstract][Full Text] [Related]
19. Epithelial cell adhesion molecule-targeted drug delivery for cancer therapy.
Simon M; Stefan N; Plückthun A; Zangemeister-Wittke U
Expert Opin Drug Deliv; 2013 Apr; 10(4):451-68. PubMed ID: 23316711
[TBL] [Abstract][Full Text] [Related]
20. Transforming doxorubicin into a cancer stem cell killer via EpCAM aptamer-mediated delivery.
Xiang D; Shigdar S; Bean AG; Bruce M; Yang W; Mathesh M; Wang T; Yin W; Tran PH; Al Shamaileh H; Barrero RA; Zhang PZ; Li Y; Kong L; Liu K; Zhou SF; Hou Y; He A; Duan W
Theranostics; 2017; 7(17):4071-4086. PubMed ID: 29158811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
